Adalimumab for induction of remission in Crohn's disease

This review (3 RCTs; n=714) found high-certainty evidence to suggest adalimumab is superior to placebo for induction of clinical remission and clinical response in moderate to severely active disease, but its effect on adverse events is uncertain due to the low number of events.


Cochrane Database of Systematic Reviews